Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Readying Xolair Biosimilar Challenge

Executive Summary

Glenmark has received US FDA clearance of an IND to start clinical studies with a proposed biosimilar version of Xolair. The Indian company appears confident of addressing any price-related challenges although the targeted launch is still some years away.

You may also be interested in...



Sorrento Taps China’s Mabtech For Biosimilars Deal

Sorrento Therapeutics has gained exclusive licensing rights from China’s Mabtech to develop four biosimilar and biobetter products for oncology and auto-immune diseases in western markets and Japan. China’s homegrown biopharmaceutical company has shown another example of its research capability to develop new drugs for the global market.

Six Questions For Sun Pharma MD Shanghvi

Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.

With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership

Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.

Topics

Related Companies

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel